Network pharmacology and bioinformatics analysis identify potential therapeutic effects of berberine on colon cancer complicated with radiation enteritis

Abstract

Objective: Patients with colon adenocarcinoma (COAD) who undergo radiation therapy develop radiation enteritis (RE). The predictive value of RE in COAD is yet to be established. Berberine, an active compound derived from the traditional Chinese medicinal plant, Coptis chinensis, has notable anti-inflammatory properties and offers protection to the intestinal mucosa. This study aimed to evaluate the possible therapeutic effect and mechanism of berberine as a treatment for COAD complicated with RE (COAD&RE).
Methods: Relevant genetic features of diverse COAD&RE populations were analyzed using bioinformatics and the Cox proportional hazards regression model. The therapeutic targets of berberine were predicted using network pharmacology and molecular docking. In vivo and in vitro experiments were conducted to validate the core genes identified using molecular docking.
Results: RE has a certain impact on the prognosis of COAD and berberine may play an important role in the treatment of COAD&RE. In addition, we identified five core therapeutic targets of berberine by network pharmacology and molecular docking: CCND1, MYC, AR, LEP, and CYP19A1. In vivo experiments showed that berberine increased short-term survival rate, body weight, and intestinal epithelial cell recovery in mice after radiation. In an in vitro study, berberine promoted the proliferation of human intestinal epithelial cells and enhanced the radiosensitivity of HT29 cells after radiation, and the relative mRNA expression levels of CCND1 and MYC closely correlated with these effects.
Conclusions: This study predicted the potential therapeutic effects of berberine on COAD&RE and verified the relevant mechanisms, which may provide insights and suggestions for the clinical treatment of COAD&RE.

Keywords

Berberine / Bioinformatics analysis / Colon adenocarcinoma / Prognosis / Radiation enteritis

参考文献

[[1]] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer [J] Clin. 2021;71(3):209-249.

[[2]] Pellino G, Warren O, Mills S, et al. Comparison of Western and Asian guidelines concerning the management of colon cancer. Dis Colon Rectum. 2018;61(2):250-259.

[[3]] Haddock MG. Intraoperative radiation therapy for colon and rectal cancers: a clinical review. Radiat Oncol. 2017;12(1):11.

[[4]] Hawkins AT, Ford MM, Geiger TM, et al. Neoadjuvant radiation for clinical T4 colon cancer: a potential improvement to overall survival. Surgery. 2019;165(2):469-475.

[[5]] Wang JS, Wang HJ, Qian HL. Biological effects of radiation on cancer cells. Mil Med Res. 2018;5(1):20.

[[6]] De Ruysscher D, Niedermann G, Burnet NG, et al. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13.

[[7]] Wang L, Wang J.[Chinese consensus on diagnosis and treatment of radiation proctitis (2018)]. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21(12):1321-1336.

[[8]] Dahiya DS, Kichloo A, Perisetti A, et al. Radiation proctitis: predictors of mortality and inpatient outcomes in the United States. Ann Gastroenterol. 2022;35(1):63-67.

[[9]] Yan T, Zhang T, Mu W, et al.Ionizing radiation induces BH(4) deficiency by downregulating GTP-cyclohydrolase 1, a novel target for preventing and treating radiation enteritis. Biochem Pharmacol. 2020;180:114102.

[[10]] Grodsky MB, Sidani SM. Radiation proctopathy. Clin Colon Rectal Surg. 2015;28(2):103-111.

[[11]] Tabaja L, Sidani SM. Management of radiation proctitis. Dig Dis Sci. 2018;63(9):2180-2188.

[[12]] Yang Y, Vong CT, Zeng S, et al. Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies. [J] Ethnopharmacol. 2021;268:113573.

[[13]] Liu D, Zhao R, Wu Y, et al. Variation in the efficacy of anti-ulcerative colitis treatments reveals the conflict between precipitating compatibility of traditional Chinese medicine and modern technology: a case of Scutellaria-Coptis. Front Pharmacol. 2022;13:819851.

[[14]] Wang J, Wang L, Lou GH, et al. Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm Biol. 2019;57(1):193-225.

[[15]] Xiong J, Wang L, Fei XC, et al.MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. Blood Cancer J. 2017;7(7):e582.

[[16]] Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun. 1982;35(2):471-475.

[[17]] Wang Y, Yi X, Ghanam K, et al. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism. 2014;63(9):1167-1177.

[[18]] Tsui H, Zi M, Wang S, et al. Smad3 couples Pak1 with the antihypertrophic pathway through the E3 ubiquitin ligase, Fbxo32. Hypertension. 2015;66(6):1176-1183.

[[19]] Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020;14(5):564-582.

[[20]] Li C, Xi Y, Li S, et al. Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. Mol Immunol. 2015;67(2 Pt B):444-454.

[[21]] Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. [J] Physiol. 2012;590(5):1035-1044.

[[22]] Li GH, Zhang YP, Tang JL, et al. Effects of berberine against radiation-induced intestinal injury in mice. Int [J] Radiat Oncol Biol Phys. 2010;77(5):1536-1544.

[[23]] Eaker EY, Sninsky CA. Effect of berberine on myoelectric activity and transit of the small intestine in rats. Gastroenterology. 1989;96(6):1506-1513.

[[24]] Taylor CT, Baird AW. Berberine inhibition of electrogenic ion transport in rat colon. Br [J] Pharmacol. 1995;116(6):2667-2672.

[[25]] Shan CY, Yang JH, Kong Y, et al. Alteration of the intestinal barrier and GLP2 secretion in berberine-treated type 2 diabetic rats. [J] Endocrinol. 2013;218(3):255-262.

[[26]] Liu X, Zhang N, Liu Y, et al.MPB, a novel berberine derivative, enhances lysosomal and bactericidal properties via TGF-beta-activated kinase 1-dependent activation of the transcription factor EB. FASEB J. 2019;33(1):1468-1481.

[[27]] Yan F, Wang L, Shi Y, et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am [J] Physiol Gastrointest Liver Physiol. 2012;302(5):G504-G514.

[[28]] Imenshahidi M, Hosseinzadeh H. Berberis vulgaris and berberine: an update review. Phytother Res. 2016;30(11):1745-1764.

[[29]] Zheng F, Tang Q, Wu J, et al. p38alpha MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. [J] Exp Clin Cancer Res. 2014;33(1):36.

[[30]] Hsu WH, Hsieh YS, Kuo HC, et al. Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol. 2007;81(10):719-728.

[[31]] Hwang JM, Kuo HC, Tseng TH, et al. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 2006;80(2):62-73.

[[32]] Qi HW, Xin LY, Xu X, et al. Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis. [J] Transl Med. 2014;12:22.

[[33]] Ho YT, Yang JS, Li TC, et al. Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett. 2009;279(2):155-162.

[[34]] Kim S, Lee J, You D, et al. Berberine suppresses cell motility through downregulation of TGF-beta1 in triple negative breast cancer cells. Cell Physiol Biochem. 2018;45(2):795-807.

[[35]] Peng PL, Kuo WH, Tseng HC, et al. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int [J] Radiat Oncol Biol Phys. 2008;70(2):529-542.

[[36]] Li R, Song Y, Ji Z, et al. Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectal cancer: network and experimental analyses. Biofactors. 2020;46(1):158-167.

[[37]] Wu K, Wei P, Liu M, et al. To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. [J] Adv Res. 2019;20:43-50.

[[38]] Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145-157.

[[39]] Su M, Guo C, Liu M, et al. Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology. Int Immunopharmacol. 2019;66:383-387.

[[40]] Li R, Ma X, Song Y, et al. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. [J] Cell Biochem. 2019;120(7):11265-11273.

[[41]] Liang Y, Zhou R, Liang X, et al. Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study. Eur [J] Pharmacol. 2020;881:173227.

[[42]] Pan Q, Zhou R, Su M, et al. The effects of plumbagin on pancreatic cancer: a mechanistic network pharmacology approach. Med Sci Monit. 2019;25:4648-4654.

[[43]] Xiao H, Qin X, Wan J, et al. Pharmacological targets and the biological mechanisms of formononetin for Alzheimer’s disease: a network analysis. Med Sci Monit. 2019;25:4273-4277.

[[44]] Li JX, Li RZ, Sun A, et al. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacol Res. 2021;171:105574.

[[45]] Pfaendler KS, Wenzel L, Mechanic MB, et al. Cervical cancer survivorship: long-term quality of life and social support. Clin Ther. 2015;37(1):39-48.

[[46]] Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. [J] Natl Compr Canc Netw. 2021;19(3):329-359.

[[47]] Liu Y, Hua W, Li Y, et al. Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis. Biochem Pharmacol. 2020;174:113776.

[[48]] Izadparast F, Riahi-Zajani B, Yarmohammadi F, et al. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle. 2022;21(22):2365-2378.

[[49]] Xiong X, Cheng Z, Wu F, et al. Berberine in the treatment of ulcerative colitis: a possible pathway through Tuft cells. Biomed Pharmacother. 2021;134:111129.

[[50]] Fang C, Guo ZQ, Chen XY, et al. Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: a meta-analysis based on 20 publications. Medicine (Baltim). 2017;96(19):e6791.

[[51]] Xie M, Zhao F, Zou X, et al. The association between CCND1 G870A polymorphism and colorectal cancer risk: a meta-analysis. Medicine (Baltim). 2017;96(42):e8269.

[[52]] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.

[[53]] Liu W, Le A, Hancock C, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA. 2012;109(23):8983-8988.

[[54]] Venkateswaran N, Lafita-Navarro MC, Hao YH, et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019;33(17-18):1236-1251.

[[55]] Housa D, Housova J, Vernerova Z, et al. Adipocytokines and cancer. Physiol Res. 2006;55(3):233-244.

[[56]] Chen W, Huang J, Xiong J, et al. Identification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancer. Oxid Med Cell Longev. 2021;2021:6290261.

[[57]] Yang H, Jin W, Liu H, et al. Immune-related prognostic model in colon cancer: a gene expression-based study. Front Genet. 2020;11:401.

[[58]] Slattery ML, Sweeney C, Murtaugh M, et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2936-2942.

[[59]] Lin J, Zee RY, Liu KY, et al. Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. Cancer Causes Control. 2010;21(6):897-908.

[[60]] Al-Mukaynizi FB, Alanazi M, Al-Daihan S, et al. CYP19A1 gene polymorphism and colorectal cancer etiology in Saudi population: case-control study. Onco Targets Ther. 2017;10:4559-4567.

[[61]] Liu M, Xu Z. Berberine promotes the proliferation and osteogenic differentiation of alveolar osteoblasts through regulating the expression of miR-214. Pharmacology. 2021;106(1-2):70-78.

[[62]] Hua R, Qiao G, Chen G, et al. Single-cell RNA-sequencing analysis of colonic lamina propria immune cells reveals the key immune cell-related genes of ulcerative colitis. [J] Inflamm Res. 2023;16:5171-5188.

[[63]] Chen Q, Li D, Wu F, et al. Berberine regulates the metabolism of uric acid and modulates intestinal flora in hyperuricemia rats model. Comb Chem High Throughput Screen. 2023;26(11):2057-2066.

版权

2024 Acupuncture and Herbal Medicine